AVITA Medical, Inc.
RCELNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for RCEL. That does not mean none is planned.
Get an email about RCEL's next catalysts
Track AVITA Medical (RCEL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.: 9–10
WebsiteNo drugs found in this phase.
Frequently asked questions
When is AVITA Medical, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for AVITA Medical, Inc. (RCEL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RCEL biotech catalysts?→
Add RCEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AVITA Medical, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.